A lot of cancer “facts” start life as convenient explanations, not carefully tested mechanisms. Personally, I think tumor necrosis is one of the clearest examples: for years we’ve treated dead tissue as the inevitable wreckage of aggressive growth. But what if that wreckage isn’t just damage—what if it’s construction material for metastasis?
At AACR 2026, new findings argued exactly that in colorectal cancer, tying neutrophil extracellular traps (NETs) to necrosis and metastatic progression. In my opinion, this is the kind of result that makes the field feel both older and newly awake at the same time: older because inflammation has been lurking in oncology for decades, newly awake because the study tries to assign NETs an active, causal role rather than a bystander one. And what makes this particularly fascinating is that it challenges a subtle psychological habit in medicine—our tendency to label anything messy as “passive.”
Necrosis shouldn’t be treated like background noise
One thing that immediately stands out is the reframing of necrosis. Personally, I think tumor necrosis has always carried a quiet stigma: clinicians look at it because it correlates with worse outcomes, but biology often gets a free pass. The newer message is that necrosis might function as part of the tumor’s strategy, not merely as a consequence of hypoxia, rapid proliferation, or poor blood supply.
What many people don’t realize is how powerful that “passive” framing has been for research priorities. If necrosis is just a symptom, then the best we can do is ignore it or measure it. But if necrosis is actively promoted by immune processes—specifically NET formation—then suddenly it becomes an intervention point.
From my perspective, this raises a deeper question: when we see tissue destruction, are we witnessing the tumor collapsing under stress, or is the tumor coordinating an immune-driven microenvironment that helps it evolve?
NETs as an engine, not just an immune artifact
NETs are web-like structures released by activated neutrophils, made of DNA, histones, and antimicrobial proteins. In theory, they’re meant to trap pathogens. In cancer, however, the problem is that biology doesn’t respect categories we draw for convenience.
Personally, I think the most unsettling angle is how NETs blur the line between defense and sabotage. They can be protective in infection, yet corrosive in chronic disease contexts, essentially turning an immune weapon into a remodeling tool for tumors.
If you take a step back and think about it, the logic is chilling but intuitive: NETs interact with vasculature and local tissue structures, which can change how cells move, survive, and seed new sites. What this really suggests is that “immune presence” doesn’t automatically mean “immune success” for the host. Sometimes immune activity can be repurposed by the tumor ecosystem.
The clinical pattern: NET-prone neutrophils and necrosis that tracks spread
The study reported that circulating neutrophils in colorectal cancer patients showed an increased tendency to form NETs. Even more interesting, researchers identified an expanded CD177-low neutrophil subset with strong NET-forming capacity but reduced ability to extravasate into tissues.
From my perspective, that detail matters because it hints at a distribution problem. It’s not just “more neutrophils equal more NETs.” Instead, the system might be dialing up trap formation in specific compartments, then delivering the effects locally in a way that still correlates with tumor architecture.
Then the team observed abundant NET accumulation within tumor necrotic regions, frequently positioned as intravascular deposits. Personally, I think this spatial relationship is where the story becomes convincing: it suggests NETs are not just associated with necrosis, but positioned to influence what happens next.
One thing that I find especially interesting is the correlation between the extent of necrosis and metastatic disease independent of tumor size. Clinically, size is a blunt instrument. If necrosis tracks metastasis beyond that, it implies necrosis is capturing “behavioral aggressiveness,” not just “how big the tumor got.”
Molecular signals: the tumor uses NET-rich environments to push aggression
The researchers also used advanced profiling approaches to examine gene programs active in NET-rich necrotic tumors. They reported activation of pathways tied to myelopoiesis (including factors like CSF1, CXCL2, and CXCL12), along with hypoxia signaling, migration-related programs, and epithelial-to-mesenchymal transition.
What many people don’t realize is that these pathways collectively describe an ecosystem shift. Myelopoiesis suggests the bone marrow and systemic immune environment may be primed to supply the right “ingredients.” Hypoxia signaling suggests the tumor’s stress responses are being amplified. Migration and EMT suggest cells are being trained to leave.
In my opinion, this is the heart of why NETs are compelling here: they sit at a junction between immune recruitment, tissue remodeling, and cell-state transitions. It’s not one isolated event. It’s a network.
And networks are exactly where tumors excel—because they can adapt. Personally, I think that’s why NETs might be more than a biomarker: they’re part of the circuitry.
The preclinical proof: block NETs, reduce necrosis, reduce metastasis
In orthotopic colorectal cancer models, progression coincided with rising circulating neutrophils, bone marrow activity skewed toward myelopoiesis, and increasing NET deposition in necrotic tumor regions. Importantly, when NET formation was inhibited genetically or pharmacologically, intratumoral necrosis dropped—and metastatic burden dropped along with it.
Personally, I think the causal language here is what separates this from many earlier “association” stories in oncology. Correlation can be elegant and still be misleading. Causation, even in preclinical settings, is where therapeutic logic becomes real.
From my perspective, there’s also a strategic implication: if NET inhibition reduces both necrosis and metastasis, then necrosis may be serving as a functional stepping stone in metastasis—not merely a byproduct.
This is where I admit my own skepticism has been historically warranted. Anti-inflammatory ideas in cancer sometimes disappoint because inflammation is context-dependent. NETs are not “just inflammation.” They’re a specific immune mechanism with specific downstream effects, and targeting a mechanism rather than a mood could be a meaningful difference.
Biomarker potential—and the danger of simplifying the immune landscape
The identification of a particular neutrophil subset with NET-forming capacity raises the possibility of biomarkers. Personally, I think this is exciting but also slightly risky. It’s tempting to treat biomarkers like switches you can flip—measure it, act, done.
But immune landscapes are dynamic. The study even suggested compartment-level complexity, like reduced extravasation despite strong NET formation. That means a biomarker might report immune programming without guaranteeing where and when the effect happens in tissues.
What this really suggests is that we may need biomarker strategies that combine timing, location, and mechanism—not just “high vs low.” If we don’t, we could end up with predictive markers that are only predictive under certain conditions.
Broader trend: oncology is slowly admitting “immunity” is not a side character
This work fits a larger pattern in cancer science: the field has been moving from viewing immunity as a backdrop to treating it as a driver of tumor evolution. Personally, I think NETs are one of the clearer examples of how innate immune behavior can become part of the tumor’s playbook.
A detail worth reflecting on is the tumor-immune feedback loop. NETs can shape the microenvironment, but the microenvironment also shapes neutrophil behavior through signaling factors linked to myelopoiesis and hypoxia. It’s a loop, and loops are hard to break with blunt interventions.
If NET targeting becomes a real strategy, it may also reshape how we think about combination therapies. Personally, I suspect NET inhibition could be paired with other treatments that rely on vascular integrity or immune recognition, because NETs already appear tied to intravascular deposits and tissue remodeling.
Where I think this could go next
Personally, I think the most important next step is translation: what does NET inhibition look like in patients where infection risk and immune function are major concerns? NETs have legitimate protective roles. If we blunt them, we need to understand the safety trade-offs and whether the therapy needs to be localized, timed, or selective.
There’s also a practical clinical question: will targeting NET formation benefit all colorectal cancer patients, or mainly those with NET-rich necrotic phenotypes? From my perspective, the future of oncology is not one-size-fits-all drugs. It’s identifying the subgroup where the mechanism actually matters.
Final takeaway
What this study suggests to me is that tumor necrosis may be less like a tragic end-state and more like a deliberately leveraged process. Personally, I think the shift from “passive necrosis” to “NET-driven necrosis” is not just a technical update—it’s a philosophical one about how we interpret tissue damage.
If necrosis can be mechanistically tied to metastasis, then we’re not only measuring aggressiveness; we’re uncovering levers. And as the field keeps learning to treat immune mechanisms as causal pathways rather than background noise, strategies like NET targeting could become part of a more intelligent, mechanistic anti-metastatic approach.
Would you like me to write a second version of this article tailored for a medical audience (more mechanistic language) or a general audience (more accessible metaphors and fewer technical terms)?
